Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXERVATE vs ACTICLATE CAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply,Off-label: Treatment of pressure ulcers, venous stasis ulcers
Treatment of infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, and acne vulgaris
1 drop in the affected eye(s) twice daily, approximately 6 hours apart.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
Terminal elimination half-life of Cenegermin is approximately 12 hours following topical ocular administration, supporting once-daily dosing
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Becaplermin is a protein that is expected to be degraded into small peptides and amino acids via general protein catabolism; specific hepatic metabolism is not a significant pathway.
Primarily hepatic; metabolites include 4-epimino derivatives; not significantly metabolized via CYP450.
Primarily renal elimination of the active metabolite (Cenegermin) as small peptides and amino acids; unchanged drug excretion is negligible
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Cenegermin binding to plasma proteins is minimal (<10%) due to its small protein nature
90-95% bound to serum proteins, primarily albumin
Vd not determined for topical ocular route; systemic exposure is low, with Vd estimated less than 0.1 L/kg based on limited systemic absorption
0.75 L/kg (50-70 L in adults); distributes well into tissues including bone, teeth, and synovial fluid
Topical ocular: Systemic bioavailability is negligible (<1%) due to low corneal penetration and extensive proteolysis at the ocular surface
Oral: 90-100% (capsule); food or dairy reduces absorption by up to 50%
No dose adjustment required for renal impairment.
e GFR 30-59 m L/min: 350 mg once daily; e GFR <30 m L/min: not recommended.
No dose adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B or C: 175 mg once daily.
Safety and efficacy in pediatric patients have not been established.
Not established for children <12 years; for ≥12 years, same as adult dosing.
No specific dose adjustment required; use same dosing as adults.
Initiate at 175 mg once daily; titrate cautiously based on renal function.
OXERVATE has been associated with an increased risk of mortality from secondary malignancies in patients who have had a malignant neoplasm. The drug should not be used in patients with active malignancy.
Photosensitivity: severe sunburn can occur with sun exposure; discontinue if photosensitivity occurs. Tooth development: use during tooth development (last half of pregnancy, infancy, childhood to age 8) may cause permanent tooth discoloration. Bone growth: may retard bone growth in premature infants. Renal toxicity: may cause azotemia, hyperphosphatemia, and acidosis. Avoid in renal impairment.
Increased risk of malignancy in patients with a history of malignancy; application to ulcers with malignant cells may promote tumor growth; use only on clean, non-infected ulcers; monitor for signs of infection; avoid application to wounds with exposed bone, tendon, or joint capsule.
Photosensitivity, tooth discoloration, bone growth retardation, renal impairment, hepatotoxicity, increased intracranial pressure, superinfection, and use in pregnancy/lactation.
Known hypersensitivity to becaplermin or any product component; active neoplasm at the application site; patients with a history of malignancy (relative contraindication based on black box warning).
Hypersensitivity to tetracyclines, pregnancy, breastfeeding, children under 8 years, renal impairment, and concurrent use with oral retinoids.
None known; no significant food interactions reported.
Avoid food and beverages for at least 1 hour before and after administration, as they can reduce the efficacy of activated charcoal. Do not mix with milk or ice cream, as they decrease binding capacity. Administer with water or a non-carbonated, non-alcoholic drink.
OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: unknown risk; second and third trimesters: unknown risk.
First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known to cause permanent tooth discoloration (enamel hypoplasia) and reversible inhibition of bone growth; use contraindicated after 15 weeks gestation.
No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; M/P ratio unknown.
Tetracyclines are excreted in breast milk but absorption by the infant is limited due to chelation with milk calcium; M/P ratio for doxycycline is approximately 0.3-0.4. Theoretical risk of tooth staining and bone inhibition, but clinical significance is low with short-term use; caution with prolonged therapy.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use standard dosing with caution.
No dosage adjustment is typically recommended for doxycycline in pregnancy due to minimal pharmacokinetic changes; however, use is generally avoided in the second and third trimesters. If indicated, standard dosing may be used in the first trimester with caution.
OXERVATE (cenegermin-bkbj) is a recombinant human nerve growth factor for neurotrophic keratitis. Administer as one drop in the affected eye(s) six times daily at 2-hour intervals for 8 weeks. Refrigerate at 2-8°C; do not freeze. Protect from light. Discard unused drops after 1 week of first opening. Monitor for corneal epithelial defect closure. Use with caution in patients with active ocular infections or inflammation.
ACTICLATE CAP is a high-dose activated charcoal formulation used for acute poisoning or overdose. Administer within 1 hour of ingestion for optimal efficacy. Do not use in patients with impaired consciousness unless the airway is protected. Monitor for vomiting and ensure rapid administration via nasogastric tube if necessary. Not effective for alcohols, metals, or caustics.
Wash hands before each use.,Instill one drop in the affected eye(s) every 2 hours, 6 times daily.,Refrigerate the medication at all times; do not freeze.,Use within 1 week after opening the vial.,Avoid touching the dropper tip to any surface.,Do not use contact lenses during treatment.,Report any eye pain, redness, or vision changes immediately.,Complete the full 8-week course even if symptoms improve.
Take ACTICLATE CAP only if directed by a healthcare professional after a poisoning or overdose.,This medication is not for regular use; it is a one-time emergency treatment.,Avoid taking this with food or drinks; take on an empty stomach for best absorption of toxins.,You may experience black stools or vomiting; this is normal.,Seek immediate medical attention if you have trouble swallowing, severe vomiting, or signs of bowel obstruction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXERVATE vs ACTICLATE CAP, answered by our medical review team.
OXERVATE is a Growth Factor (Ophthalmic) that works by OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.. ACTICLATE CAP is a Tetracycline Antibiotic that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXERVATE and ACTICLATE CAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXERVATE is: 1 drop in the affected eye(s) twice daily, approximately 6 hours apart.. The standard adult dose of ACTICLATE CAP is: 350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXERVATE and ACTICLATE CAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXERVATE is classified as Category C. OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducte. ACTICLATE CAP is classified as Category C. First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.